Pricing Log in Create free account
Friday 6 November 2026 Export AMLX’s income statement to Excel — free account

Amylyx Pharmaceuticals, Inc.

AMLX Healthcare Drug Manufacturers Specialty & Generic

Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023.

Revenue
−100.6%
EPS
+15.2%
Free cash flow
−24.5%

Quarter to June 2026, against a year earlier

27.79 1.61 −5.48%
Market cap
$3.5B
P/E
0.0×
Fwd P/E
−9.2×
Dividend yield
—
F-score
3/9
Altman Z
−2.95
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.15
Sold, $m 10.04
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy 1 — — — — 1 — — — — — —
Sell — 5 5 5 — — — 1 — 5 1 —
Insider Ownership 4.40%

Capital & Financial Ratios $m

Size
Market Cap 3,470.00
Revenue ttm 87.37
Net income ttm (152.09)
Free cash flow ttm (130.72)
Net debt Q (250.76)
Valuation
P/E 0.00
Forward P/E (9.21) (negative: loss-making)
Price / sales 35.37 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 12.92 (above 6: high)
Financial health
Current ratio Q 12.12 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q —
Growth
Revenue growth Q −100.61% (below 0%: shrinking)
Operating income growth Q −6.62% (below 0%: shrinking)
EPS, this year +1.70%
EPS, next year A +25.63% (at or above 15%: strong)
Revenue, next year A −61.29% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +47.73% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 32.5×, against a ten-year median of 5.7×; over the ten years it ranged from −0.6× in 2024 to 40.1× in 2026.
P/S against its own 10 years 95.13%
10-year low 10-year high
P/B against its own 10 years 91.00%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—
Growth, 2017–25
−100.0%/yr
  1. 0.60 ’17
  2. 0.42 ’18 −30
  3. 0.00 ’22 −100
  4. 0.00 ’23
  5. 0.00 ’24
  6. 0.00 ’25
paid change on the year, %

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 371 177 317 251
Receivables 40 0 0 —
Inventory 38 — — —
Other — — — —
465 189 324 256
2023 2024 2025 Q'26
Payables 22 3 4 6
ST’ Debt — — — —
Other — — — —
82 28 23 21

Compound Annual Growth %

10y 5y 3y
Sales — — 574.28%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 124.63% (3.59%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.36 Actual −0.39

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.43 −0.37 Beat by 0.06
Q4 FY25 −0.31 −0.30 Beat by 0.01
Q1 FY26 −0.34 −0.37 Miss by 0.03
Q2 FY26 −0.36 −0.39 Miss by 0.03
Q3 FY26 −0.38 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.37) (0.39) — — —
’25 (0.42) (0.46) (0.37) (0.30) (1.53)
’24 (1.75) (1.07) (1.07) (0.55) (4.43)
’23 0.02 0.31 0.30 0.07 0.70
’22 (0.93) (0.93) (0.92) (0.65) (3.39)
’21 (2.33) (3.41) (3.42) (4.19) (13.35)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’24 89 (1) 0 (1) 87
’23 71 98 103 108 381
’22 — — 0 22 22
’21 — — 0 — 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (37) (31) — — —
’25 (40) (25) (30) (28) (123)
’24 0 (67) (42) (59) (168)
’23 (5) 9 (5) 14 12
’22 (41) (46) (43) (50) (180)
’21 (13) (13) (21) (28) (75)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (41) (31) — — —
’25 (40) (25) (30) (28) (123)
’24 (1) (67) (78) (59) (204)
’23 (5) 8 (6) 13 11
’22 (41) (48) (44) (50) (182)
’21 (13) (13) (21) (28) (75)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — — 1 0 22 381 87 — 87 +240.5% 28 28 177 +150.0%
Gross margin, % — — — — 100.00 100.00 86.54 93.32 (42.65) — (42.65) (142.6) pt
EBT — — — — (42) (88) (198) 54 (302) (145) (152) +27.9%
EBT margin, % — — — — (6,504.62) (30,852.98) (888.89) 14.26 (345.81) 0.00 0.00 +6,504.6 pt
Net income — 0 — — (42) (88) (198) 49 (302) (145) (152) n/m
Per share, $
Per share, $ Revenue — — — — 0.11 0.04 0.38 5.66 1.28 0.00 0.00 n/m
Earnings — — — — (6.96) (13.35) (3.39) 0.73 (4.43) (1.53) (1.43) (26.1%)
Cash flow — — — — (6.04) (11.36) (3.07) 0.18 (2.46) (1.30) (1.14) (26.4%)
Capex — — — — (0.02) (0.05) (0.04) (0.02) (0.53) 0.00 (0.04) (42.9%)
Free cash flow — — — — (6.06) (11.41) (3.12) 0.16 (2.99) (1.31) (1.18) (26.4%)
Book value — — — — 0.88 13.39 5.82 6.45 2.42 3.23 2.15 +29.7%
Shares, m — — — — 6 7 58 67 68 95 102 +73.1%
Valuation, ×
Valuation, × P/E — — — — 0.00 0.00 0.00 20.51 0.00 — 0.00 4.1
P/S — — — — 0.00 0.00 0.00 2.64 2.95 — 35.37 1.1
P/B — — — — 0.00 0.00 6.18 2.32 1.56 — 12.92 2.0
EV/Sales — — — — 0.00 0.00 0.00 1.67 0.94 — 32.51 0.5
EV/FCF — — — — (0.32) (0.32) (9.64) 59.61 (0.40) — (21.73) 9.8
Cash, $m
Cash, $m Operating cash flow — — — — (37) (75) (180) 12 (168) (123) (127) +27.4%
Capex — — — — 0 0 (3) (1) (36) 0 (4) (1.8%)
Free cash flow — — — — (37) (75) (182) 11 (204) (123) (131) +27.4%
Balance, $m
Balance, $m Working capital — — — — 6 88 336 383 161 301 235 +116.6%
Net debt — — — — (11) (96) (347) (371) (177) (317) (251) +94.3%
Shareholders’ equity — — — — 5 88 341 433 165 305 239 +124.6%
Returns, %
Returns, % ROA — — — — (599.55) (146.90) (79.82) 10.84 (84.87) (55.00) (66.25) +544.6 pt
ROIC — — — — 0.00 0.00 0.00 39.07 0.00 0.00 0.00 0.0 pt
ROE — — — — 0.00 80.71 (209.43) 12.73 (100.88) (61.59) (74.73) (61.6) pt
People
People Employees — — — — 110 205 262 384 123 136 — +4.3%
Revenue/emp, $m — — — — 0.01 0.00 0.08 0.99 0.71 0.00 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2024 · latest quarter Dec 2024

Amylyx Pharmaceuticals, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
HIMS Hims & Hers Health, Inc. $5.6B — (loss-making) — (loss-making) +38.25% (above 0%: growing) n/m +5.09% (above 0%: growing) 63.83% (12.90%) Compare
SUPN Indivior Pharmaceuticals Inc. $5.6B 7.6× 9.5× +13.38% (above 0%: growing) +241.47% (above 0%: growing) +240.68% (above 0%: growing) 85.67% 50.84% Compare
LQDA Liquidia Corporation $4.0B 28.5× 22.1× +1,842.73% (above 0%: growing) n/m +270.23% (above 0%: growing) 93.27% 49.81% Compare
AMLX Amylyx Pharmaceuticals, Inc. $3.5B — (loss-making) — (loss-making) −100.61% (below 0%: shrinking) n/m −24.50% (below 0%: shrinking) 100.00% 0.00%
RGC Regencell Bioscience Holdings Limited $2.6B — (loss-making) — — — +57.15% (above 0%: growing) 0.00% — Compare
HCM HUTCHMED (China) Limited Sponsored ADR $2.5B — (loss-making) — +510.07% (above 0%: growing) +419.25% (above 0%: growing) +113.21% (above 0%: growing) 60.90% 0.00% Compare
PRGO Perrigo Company plc $2.2B — (loss-making) — (loss-making) −5.24% (below 0%: shrinking) n/m +138.48% (above 0%: growing) 32.45% 2.34% Compare
PBH Prestige Consumer Healthcare Inc. $2.1B 13.7× 11.7× +22.69% (above 0%: growing) −38.37% (below 0%: shrinking) −38.18% (below 0%: shrinking) 51.30% 24.00% Compare
TRLV Trulieve Cannabis Corp. $2.1B — (loss-making) — (loss-making) −20.12% (below 0%: shrinking) n/m +24.49% (above 0%: growing) 64.30% 0.00% Compare
Median of peers $2.5B 13.7× 11.7× +22.69% +241.47% +85.18% 62.37% 2.34%

All 84 Drug Manufacturers Specialty & Generic stocks →

Pay and ownership Proxy statement filed 23 April 2026

Ownership

Directors and executive officers, together 10.90%
FMR LLC 14.80%
Perceptive Advisors LLC 8.10%
BlackRock, Inc 7.00%
TCG Crossover GP II, LLC 5.60%
The Vanguard Group 5.20%
Commodore Capital LP 5.10%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Amylyx Pharmaceuticals, Inc. (AMLX) Latest News

5 Nov

Impact 4 · · Moby
Impact 4 · · The Motley Fool transcript
Impact 4 · · MarketBeat transcript
Impact 4 · · Business Wire

6 Oct

Impact 4 · · Business Wire

3 Oct

Impact 4 · · MarketBeat

1 Sep

Impact 4 · · The Motley Fool

21 Aug

Impact 5 ·
Impact 4 · · The Motley Fool

19 Aug

Impact 4 ·
Impact 4 ·
Impact 3 ·

18 Aug

Impact 5 · · Barchart
Impact 5 ·
Impact 5 · · InvestorsHub
Impact 5 ·
Impact 4 ·
Impact 4 · · The Motley Fool
Impact 4 · · Stocktwits
Impact 4 · · qz.com
Impact 4 ·
Impact 4 · · MarketBeat
Impact 4 ·
Impact 4 ·
Impact 4 ·
Impact 4 ·
Impact 4 · · biopharmadive.com
Impact 3 ·

17 Aug

Impact 4 ·
Impact 3 · · Stocktwits

AMLX metrics, ten years each

stockrow.com/AMLX · Data as of Dec 31, 2024 · For information only; not investment advice. · © 2026 stockrow.com